Double-barreled cell therapy takes aim at hard-to-treat blood cancers

This early-phase study tests a new treatment using a patient's own immune cells, engineered to attack two cancer targets (CD19 and BCMA), for people with certain blood cancers (like multiple myeloma or lymphoma) that have returned or stopped responding to standard therapy. About 20 participants will receive the cells to see if it is safe and can shrink tumors. The goal is to control the disease, not necessarily cure it, and patients may need ongoing monitoring.